Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Stock Slides 10 Percent on Missed Q2 Revenues

NEW YORK (GenomeWeb News) – Shares in Invitrogen were down approximately 9.8 percent, or $6.10, at $56.23 in mid-afternoon trading today after the company reported lower-than-expected revenues for the second quarter, and lowered its financial guidance.
As GenomeWeb News reported this morning, Invitrogen posted $313 million in total revenues for the quarter. Analysts had expected Invitrogen to report $320 million. The company now expects 2006 revenue to be between $1.26 billion and $1.30 billion, down from the $1.30 billion to $1.35 billion it projected in April.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.